Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

About this update from Pulse Biosciences, Inc

HAYWARD, Calif. --(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference . Pulse Biosciences’ Management is scheduled to present on Wednesday, March 18, 2026 , at 10:40 am ET . A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/ . About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences , nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. View source version on businesswire.com : https://www.businesswire.com/news/home/20260305531169/en/ Investors: Pulse Biosciences, Inc. Jon Skinner , CFO [email protected] Or Gilmartin Group Philip Trip Taylor 415.937.5406 [email protected] Source: Pulse Biosciences, Inc.

View stock analysis, news, and events for Pulse Biosciences, Inc